Establishment Labs Holdings Inc. (NASDAQ:ESTA) Shares Acquired by Assenagon Asset Management S.A.

7 months ago
47 Views

Assenagon Asset Management S.A. lifted its stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA – Free Report) by 357.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 30,247 shares of the company’s stock after acquiring an additional 23,639 shares during the quarter. Assenagon Asset Management S.A. owned 0.12% of Establishment Labs worth $783,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Millennium Management LLC raised its position in Establishment Labs by 2,021.2% in the second quarter. Millennium Management LLC now owns 419,059 shares of the company’s stock valued at $22,788,000 after purchasing an additional 399,303 shares during the period. Cowen AND Company LLC raised its holdings in shares of Establishment Labs by 18.1% in the 3rd quarter. Cowen AND Company LLC now owns 1,141,172 shares of the company’s stock valued at $55,997,000 after buying an additional 175,000 shares during the period. Neuberger Berman Group LLC raised its holdings in shares of Establishment Labs by 45.7% in the 3rd quarter. Neuberger Berman Group LLC now owns 496,098 shares of the company’s stock valued at $27,092,000 after buying an additional 155,532 shares during the period. Morgan Stanley lifted its stake in Establishment Labs by 98.3% during the 4th quarter. Morgan Stanley now owns 302,422 shares of the company’s stock worth $19,854,000 after acquiring an additional 149,925 shares in the last quarter. Finally, Iron Triangle Partners LP boosted its stake in shares of Establishment Labs by 26.6% during the second quarter. Iron Triangle Partners LP now owns 537,906 shares of the company’s stock worth $36,906,000 after buying an additional 112,906 shares during the period. Hedge funds and other institutional investors own 72.91% of the company’s stock.

Shares of Establishment Labs stock opened at $54.16 on Friday. Establishment Labs Holdings Inc. has a 12-month low of $16.96 and a 12-month high of $79.88. The company has a current ratio of 3.06, a quick ratio of 1.67 and a debt-to-equity ratio of 10.26. The stock has a market cap of $1.47 billion, a PE ratio of -17.82 and a beta of 1.24. The company has a 50-day moving average of $44.28 and a two-hundred day moving average of $35.99.

Establishment Labs (NASDAQ:ESTA – Get Free Report) last issued its quarterly earnings data on Wednesday, February 28th. The company reported ($0.79) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.95) by $0.16. Establishment Labs had a negative net margin of 47.53% and a negative return on equity of 357.81%. The business had revenue of $31.60 million during the quarter, compared to analysts’ expectations of $31.44 million. During the same period last year, the company posted ($0.55) EPS. The company’s revenue was down 27.9% on a year-over-year basis. On average, research analysts anticipate that Establishment Labs Holdings Inc. will post -1.58 EPS for the current fiscal year.

Several equities research analysts have recently weighed in on ESTA shares. Mizuho increased their target price on shares of Establishment Labs from $50.00 to $65.00 and gave the stock a “buy” rating in a research note on Monday, April 1st. Citigroup increased their target price on shares of Establishment Labs from $49.00 to $60.00 and gave the stock a “buy” rating in a research note on Wednesday. JPMorgan Chase & Co. increased their target price on shares of Establishment Labs from $46.00 to $53.00 and gave the stock an “overweight” rating in a research note on Thursday, February 29th. Finally, Stephens restated an “overweight” rating and issued a $47.00 price objective on shares of Establishment Labs in a research report on Thursday, January 11th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, Establishment Labs presently has a consensus rating of “Buy” and a consensus target price of $63.33.

Get Our Latest Stock Analysis on Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.
• Five stocks we like better than Establishment Labs
• Beazer Homes USA is an Overlooked Opportunity in Housing
• High Dividend REITs: Are They an Ideal Way to Diversify?
• 5 Stocks in the Current Bull Market with Upside to Come

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should you invest $1,000 in Establishment Labs right now?

Before you consider Establishment Labs, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Establishment Labs wasn’t on the list.

While Establishment Labs currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here…Read more by MarketBeat

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

IJNN

FREE
VIEW